Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

3.22
-0.0600-1.83%
Post-market: 3.20-0.0200-0.62%18:30 EDT
Volume:232.06K
Turnover:756.28K
Market Cap:48.68M
PE:-1.01
High:3.34
Open:3.26
Low:3.17
Close:3.28
52wk High:10.00
52wk Low:2.13
Shares:15.12M
Float Shares:9.60M
Volume Ratio:0.58
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1959
EPS(LYR):-2.9824
ROE:-107.62%
ROA:-60.80%
PB:2.12
PE(LYR):-1.08

Loading ...

CervoMed Updates Investor Presentation and Disclosure Practices

TIPRANKS
·
2 hours ago

CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 05

Hopeful Week For Insiders Who Bought US$3.46m Of CervoMed Stock

Simply Wall St.
·
Oct 01

Canaccord Genuity Sticks to Its Buy Rating for CervoMed (CRVO)

TIPRANKS
·
Sep 29

CervoMed Advances Neflamapimod Tablet and Dosing Strategy

TIPRANKS
·
Sep 29

CervoMed: Improved Dosing, Safety Margin and CMC Profile Bolster Confidence in 100 mg BID Regimen; Buy Rating and $12 Price Target Reiterated

TIPRANKS
·
Sep 28

CervoMed neflamapimod update removes key overhang, says Jones

TIPRANKS
·
Sep 28

CervoMed announces PK results with new neflamapimod oral tablet formula

TIPRANKS
·
Sep 28

CervoMed Plans Neflamapimod 100 Mg Twice-Daily Regimen for Future Clinical Trials

Reuters
·
Sep 28

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

THOMSON REUTERS
·
Sep 28

CervoMed - Introduces New 50 Mg Neflamapimod Tablet for Twice-Daily Dosing

THOMSON REUTERS
·
Sep 28

CervoMed - New 50 Mg Tablet Meets Primary Objectives in Phase 1 Study

THOMSON REUTERS
·
Sep 28

CervoMed Joins ROTH Healthcare Opportunities Conference Neuroscience Panel

Reuters
·
Sep 22

CervoMed highlights late-breaking neflamapimod Phase 2a data

TIPRANKS
·
Sep 11

CervoMed Neflamapimod Phase 2a nfvPPA Biomarker Data Set for ISFTD 2026 Oral Session

Reuters
·
Sep 10

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026

THOMSON REUTERS
·
Sep 10

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

GlobeNewswire
·
Sep 10

CervoMed to Participate in September Investor Conferences

GlobeNewswire
·
Sep 08

CervoMed price target lowered to $7 from $9 at Roth Capital

TIPRANKS
·
Aug 20

CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 12